Pfizer takeover target ResApp has had its valuation cut after its COVID-19 detecting cough tool failed to meet performance requirements needed to lock in an improved all-cash offer for the business.
21/06/2022 - 11:47
ResApp deal dips on test results
21/06/2022 - 11:47
Your single user subscription provides more than you think
Extensive & innovative
WA business database
WA business database
The most powerful knowledgebase mapped from 20 years of research and insight into every WA
leader and business.
Never miss a story with
BN daily emails
BN daily emails
Morning and afternoon timely wrap ups of every news item delivered straight to your device.
Directors, businesses
lists and projects
lists and projects
Transaction records, directors wealth, remuneration data and network activity.
Specialised reports
and profile events
and profile events
Get the inside scoop on every news story and connect with WA’s biggest leaders.
Just want the daily emails? Sign up to our free newsletters
